# Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function

> **NCT01794663** · PHASE2 · COMPLETED · sponsor: **Opsona Therapeutics Ltd.** · enrollment: 252 (actual)

## Conditions studied

- Delayed Graft Function

## Interventions

- **DRUG:** OPN-305
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01794663
- **Lead sponsor:** Opsona Therapeutics Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2016-06-30
- **Final completion:** 2016-06-30
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2017-02-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01794663

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01794663, "Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01794663. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*